An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.
Phase of Trial: Phase I/II
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; CCS 1477 (Primary) ; Enzalutamide (Primary) ; Prednisolone; Prednisone
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors CellCentric
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 02 Jul 2018 Status changed from not yet recruiting to recruiting.
- 02 Jul 2018 New trial record